PEPTIDE GUARDIANResearch literacy for peptides

Guides

Metabolic: what the research shows

Compounds studied for body weight, appetite and blood sugar. This guide covers 7 of them. For each one: what is established in people, the key studies, and its status.

From our publisherAMINOSWORK, the research peptide supplier behind Peptide Guardian, posts its third-party lab reports by lot number. Open the lab report library

5-Amino-1MQ

Animal and cell studies only

5-Amino-1MQ is a small lab-made molecule, not a peptide, that blocks an enzyme called NNMT; it reduced fat gain and improved aged muscle in small mouse studies, mostly from one university group and its spin-out company, and it has never been tested in people.

Nothing is established in people. On 18 November 2026 I searched PubMed and ClinicalTrials.gov and found no published or registered human study of 5-amino-1MQ or of any other NNMT-blocking drug. The only human research on NNMT is observational: it measured the enzyme in people's fat tissue and linked higher levels to type 2 diabetes and insulin resistance, which shows an association, not that blocking it helps. Every result for 5-amino-1MQ itself comes from mice, rats or cells, in studies lasting from 11 days to 8 weeks with groups of roughly 6 to 13 animals.

Key studies

  • Animal study, 2026. The authors linked NNMT in kidney tubules to ageing of kidney cells, scarring and loss of kidney function in human biopsies, and reported that 'selective NNMT inhibition' was protective in cells, organoids and mice. Source: pubmed.ncbi.nlm.nih.gov
  • Animal study, 2026. NNMT was raised in the inflamed pancreas, especially in the cells that make scar tissue. Source: pubmed.ncbi.nlm.nih.gov
  • Animal study, 2025. NNMT levels were higher in leg muscle from patients with peripheral artery disease and stayed high in mouse muscle stem cells after the blockage. Source: pubmed.ncbi.nlm.nih.gov
FDA status
Not approved. Not on any compounding list. FDA warned a compounder in January 2026 for using it.
In sport
Not named on the List; S0 applies if it has no approval anywhere.

All 13 studies on the 5-Amino-1MQ page

AOD-9604

Early human trials

AOD-9604 is a lab-made 16-amino-acid piece of human growth hormone that reduced fat gain in obese rodents, but in its largest human trial, of about 500 adults, it did not produce significant weight loss and it has never been approved as a medicine.

Six company-funded, placebo-controlled trials gave AOD-9604 to people, most by mouth, for up to 24 weeks; 893 people took part in total. None showed convincing weight loss. The largest, in 502 adults with obesity over 24 weeks, missed its main goal, and the 12-week trial in 300 adults reached significance only in a subgroup of women. Development for obesity stopped in 2007. The full trial results were never published in a journal, and there are no human studies of AOD-9604 injected under the skin, which is how it is now commonly sold.

Key studies

  • Human trial, 2007. This is the largest trial. Source: sec.gov
  • Human trial, 2005. The authors reported that every AOD-9604 group lost more weight than placebo, but the differences were small and the dose pattern was irregular. Source: fda.gov
  • Human trial, 2004. In the infusion trial a blood marker of fat breakdown rose within hours, and the average weight change of about 0.6 kg over three weeks was not different from placebo. Source: fda.gov
FDA status
Not FDA-approved. Not compoundable under the 503A list; FDA advisers voted 12-0 against adding it in 2024.
In sport
Prohibited at all times (class S2.2.3, growth hormone fragments).

All 11 studies on the AOD-9604 page

Cagrilintide

Late-stage human trials

Cagrilintide is an experimental long-acting copy of the pancreatic hormone amylin, made by Novo Nordisk; large phase 3 trials of it combined with semaglutide (CagriSema) found substantial weight loss, but we found no approval for it in any country.

For cagrilintide on its own, the published human evidence is modest: one 26-week trial in 706 people showed weight loss of 6% to 11% across dose levels against 3% on placebo, and small single-drug groups inside larger trials point the same way. For the combination with semaglutide (CagriSema), placebo-controlled phase 3 trials lasting 68 weeks in several thousand adults showed large average weight loss (about 20% without diabetes and about 14% with type 2 diabetes) and better blood sugar control, with stomach and gut side effects in most participants. It is not established whether CagriSema lowers the risk of heart attack and stroke, how safe it is beyond about a year and a half, or what happens after stopping; and in the one head-to-head trial, announced by the company, it did not match tirzepatide. Every trial cited here was paid for by Novo Nordisk, and neither cagrilintide nor CagriSema is an approved medicine.

Key studies

  • Human trial, 2026. COMPANY ANNOUNCEMENT, NOT PEER REVIEWED. Source: novonordisk.com
  • Human trial, 2026. This trial's main question was whether CagriSema produces more weight loss than semaglutide alone. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2026. At 68 weeks body weight had fallen by 20.7% and 21.0% in the two CagriSema groups and by 2.0% on placebo, in the analysis that assumes people took the treatment as intended. Source: pubmed.ncbi.nlm.nih.gov
FDA status
No approval found anywhere. Novo Nordisk filed CagriSema with FDA in December 2025; no decision found yet.
In sport
Not named; with no approval found anywhere, S0 applies: prohibited at all times.

All 12 studies on the Cagrilintide page

HGH fragment 176-191

Animal and cell studies only

HGH fragment 176-191 is the last 16 amino acids of human growth hormone made as a separate peptide; it has never been tested in people, and the fat-loss research usually quoted for it was done on two different molecules (hGH 177-191 and AOD-9604), mostly in obese rodents.

No study in people has used the unmodified hGH 176-191 fragment; searches of PubMed and ClinicalTrials.gov found none. All human data come from six company-funded trials of a different molecule, AOD-9604. The largest, a 24-week trial with 502 obese adults, did not show significant weight loss compared with placebo and was never published in a journal; the company ended obesity development in 2007. The published safety summary reported side effects at rates similar to placebo, but FDA judged the safety data too limited to draw conclusions.

Key studies

  • Human trial, 2013. Safety only; no weight results are given. Source: jofem.org
  • Review, 2024. FDA reported that in the 24-week 'OPTIONS' trial (502 randomised obese adults, with diet and exercise) there was no significant difference in weight loss between AOD-9604 and placebo, and quoted the company's 2007 statement that weight loss 'was too low to reach statistical significance' at 12 or 24 weeks. Source: fda.gov
  • Animal study, 2001. Growth hormone and AOD-9604 both reduced weight gain in obese mice and raised fat burning and blood glycerol (a marker of fat breakdown). Source: pubmed.ncbi.nlm.nih.gov
FDA status
Not FDA-approved. Not on any FDA compounding category list or HHS's 2026 draft peptide list.
In sport
Prohibited at all times; named in WADA class S2.2.3 as 'hGH 176-191'.

All 11 studies on the HGH fragment 176-191 page

Retatrutide

Late-stage human trials

Retatrutide is an experimental injectable medicine from Eli Lilly that switches on three gut-hormone receptors at once; large phase 3 trials published in 2026 found substantial weight loss, but it is not an approved medicine and its long-term safety is still being studied.

In placebo-controlled trials lasting up to 80 weeks and involving several thousand adults, retatrutide produced large average weight loss (about 17% to 25% in people without diabetes in the main phase 3 trial, and about 12% to 19% in people with type 2 diabetes) and lowered blood sugar. Stomach and gut side effects were common, and more people stopped treatment because of side effects at higher doses. What is not established: safety beyond about two years, whether it lowers or raises the risk of heart attack and stroke (the trial designed to answer this is not due to finish until 2029), how it compares head-to-head with approved obesity medicines, and what happens after stopping. Every trial cited here was paid for by the manufacturer, and retatrutide is not an approved medicine.

Key studies

  • Human trial, 2026. This is the largest published retatrutide trial. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2026. At 80 weeks average body weight had fallen by 11.9% (lowest dose), 16.8% (middle dose) and 18.8% (highest dose), compared with 5.1% on placebo. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2026. In TRIUMPH-4, knee pain scores on a 0-to-10 scale fell by 3.96 and 3.74 points in the two retatrutide groups, compared with 2.12 on placebo, and body weight fell by 20.0% and 23.7%, compared with 4.6% on placebo. Source: pubmed.ncbi.nlm.nih.gov
FDA status
Not approved. Investigational drug in phase 3 trials.
In sport
Not named; with no approval found anywhere, S0 applies: prohibited at all times.

All 12 studies on the Retatrutide page

Semaglutide

Approved medicine

Semaglutide is a man-made version of the gut hormone GLP-1; it is an FDA-approved prescription medicine backed by some of the largest trials in this field, but the compounded, salt-form and "research use" versions sold online are not that approved medicine.

Semaglutide is one of the most heavily studied medicines of its kind. Large randomized trials showed that it lowers body weight (about 15% on average over 68 weeks in adults with obesity), and that it lowered the rate of heart attack, stroke or cardiovascular death in people who already had heart disease, and of worsening kidney disease in people with type 2 diabetes and kidney disease. What is less settled: most of the lost weight returned within a year of stopping, a liver disease approval rests on interim biopsy results, and two large trials found no benefit in early Alzheimer's disease. Nearly all of these trials were paid for by the maker, and none tested compounded, salt-form or "research use" products.

Key studies

  • Human trial, 2026. Semaglutide did not slow the disease. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2025. Major cardiovascular events occurred in 12.0% of the semaglutide tablet group (579 people) and 13.8% of the placebo group (668 people), a hazard ratio of 0.86 (95% confidence interval 0.77 to 0.96). Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2025. The liver inflammation resolved, without the scarring getting worse, in 62.9% on semaglutide and 34.3% on placebo. Source: pubmed.ncbi.nlm.nih.gov
FDA status
Approved prescription medicine (Ozempic, Rybelsus, Wegovy). Compounded, salt-form and research-use versions are not FDA-approved.
In sport
Not prohibited; approved, so outside S0. On the WADA Monitoring Program since 2024.

All 12 studies on the Semaglutide page

Tirzepatide

Approved medicine

Tirzepatide is a man-made peptide that acts on two gut-hormone receptors (GIP and GLP-1); it is an FDA-approved prescription medicine backed by large human trials, but the versions sold online for "research use" are not that approved medicine.

In people with type 2 diabetes, large randomized trials showed tirzepatide lowered blood sugar and body weight, and in one trial of 1,879 patients it lowered both more than semaglutide over 40 weeks. In people with obesity, a 72-week placebo-controlled trial of 2,539 adults found average weight loss of 15% to 21%, and two one-year trials found fewer breathing pauses in sleep apnea. What is less settled: weight returned in most people who stopped (SURMOUNT-4), about a quarter of the weight lost was lean mass in a small scan substudy, and the largest heart-outcomes trial showed tirzepatide was not worse than dulaglutide but did not prove it was better. Almost all of these trials were paid for by the maker, and none tested the unapproved products sold online.

Key studies

  • Human trial, 2025. On tirzepatide, body weight fell 21.3%, fat mass fell 33.9% and lean mass (which includes muscle) fell 10.9%. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2025. At 176 weeks, average weight change was -12.3%, -18.7% and -19.7% in the three tirzepatide groups, against -1.3% with placebo. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2025. Death from cardiovascular causes or a worsening heart failure event occurred in 9.9% of the tirzepatide group and 15.3% of the placebo group (hazard ratio 0.62, 95% confidence interval 0.41 to 0.95). Source: pubmed.ncbi.nlm.nih.gov
FDA status
Approved prescription medicine (Mounjaro, Zepbound). Compounded and research-use versions are not approved.
In sport
Not prohibited; approved, so outside S0. On the WADA Monitoring Program.

All 11 studies on the Tirzepatide page

Before you trust any seller

A study tells you about the compound. It tells you nothing about what is in a particular vial. How to read a lab report

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sign up and it opens right away.